Abstract:Anlotinib is an oral tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR and c-kit. In the phase Ⅲ ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced non-small-cell lung cancer (NSCLC) patients who had received at least two previous chemotherapy and epidermal growth factor receptor /anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial. Patients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE 4.0) and managed by investigators. Adverse events and key strategies for preventing and managing the most common adverse events were described. Proportions were compared using the χ2 test or Fisher’s exact test, as appropriate. Two-sided values of P <0.05 were considered statistically significant. Analyses were calculated by SAS 9.4. Between February 2015, and August 2016, a total of 437 patients were randomized to anlotinib group (n=294) and placebo group (n=143). The most common anlotinb related adverse events were hypertension (64.6%), fatigue (46.3%), TSH elevation (44.6%), hand-foot syndrome (HFS) (43.2%), hypertriglyceridemia (38.8%), anorexia (38.4%). The most common anlotinib related grade ≥3 adverse events were hypertension (13.3%), HFS (3.7%), and hypertriglyceridemia (2.4%). The median onset time of hypertension, HFS, and hypertriglyceridemia were 6 days, 30 days, and 22 days respectively. To monitor blood pressure, every patient had an electronic manometer. One hundred and eight (36.7%) patients received dihydropyridine calcium channel blockers, 79 (26.9%) patients received converting enzyme inhibitors of angiotensin /angiotensin receptor blockers, 57 (19.4%) patients received diuretics, 35 (11.9%) patients received beta-blockers. Only 3 (1.0%) patients need dose modification due to hypertension. Prophylactic measures of HFS were recommended. Frequent emollients should be used on hands and feet to maintain skin hydration, manicure or pedicure to control calluses, protect pressure points and tender areas of feet with insole cushions, shock-absorbing soles, comfortable shoes. Seven (2.3%) patients required dose reduction due to hand-foot skin syndrome. Eleven (3.7%) patients received cortisone cream for topical therapy. Twenty-four patients received fibrates to reduce plasma triglyceride level. Two (0.7%) patients required dose reduction due to hypertriglyceridemia. Anlotinb-related adverse events could be controlled by prophylactic measures, and early intervention.

Clinical development and management of adverse events associated with FGFR inhibitors

Safety Profile and Adverse Event Management for Futibatinib, an Irreversible FGFR1–4 Inhibitor: Pooled Safety analysis of 469 patients

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors

Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem

Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers

Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies

Path-45. Treatment Of Fgfr1 – Altered Who Grade 1 Glioneuronal Tumors With Fgfr Inhibitor Erdafitinib

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023

P1.01-108 Management of Anlotinib-Related Adverse Events: Data from ALTER 0303

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer

Targeting FGFR for cancer therapy

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors

Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma